他莫昔芬联合环磷酰胺治疗晚期乳腺癌的效果观察

The Effect of Tamoxifen and Cyclophosphamide in the Treatment of Advanced Breast Cancer

目的探讨他莫昔芬联合环磷酰胺在晚期乳腺癌患者中的临床效果。方法选取2015年3月—2017年7月来医院治疗的晚期乳腺癌患者78例作为研究对象。根据信封抽签原则,将其分为对照组(n=39)和观察组(n=39)。对照组采用常规NP化疗方案治疗,观察组采用他莫昔芬联合环磷酰胺治疗,比较两组临床疗效。结果观察组治疗1个周期CR+PR率为41.03%,高于对照组17.95%,差异具有统计学意义(P<0.05);两组治疗后毒副反应发生率比较,差异无统计学意义(P>0.05)。结论将他莫昔芬联合环磷酰胺用于晚期乳腺癌患者中效果理想。

Objective To investigate the clinical effect of tamoxifen combined with cyclophosphamide in patients with advanced breast cancer.Methods 78 patients with advanced breast cancer admitted from March 2015 to July 2017 were selected as the study objects.According to the random number method,they were divided into control group(n=39)and observation group(n=39).The control group was treated with conventional NP chemotherapy.The observation group was treated with tamoxifen combined with cyclophosphamide.The clinical efficacy of the two groups was compared.Results The CR+PR rate in the observation group was 41.03%in one cycle,which was higher than that in the control group 17.95%,the difference was statistically significant(P<0.05).There was no significant difference in the incidence of side effects after treatment between the two groups(P>0.05).Conclusion The effect of tamoxifen combined with cyclophosphamide in patients with advanced breast cancer is satisfactory.